Gemina Laboratories Ltd. (GLABF)
USD 0.44
(-2.91%)
USD 0.44
(-2.91%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 3.04 Million CAD | 56.23% |
| 2023 | 1.94 Million CAD | 309.06% |
| 2022 | 475.91 Thousand CAD | -79.89% |
| 2021 | 2.36 Million CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 3.04 Million CAD | 29.28% |
| 2024 FY | 3.04 Million CAD | 56.23% |
| 2024 Q2 | 1.75 Million CAD | 23.59% |
| 2024 Q3 | 2.35 Million CAD | 34.32% |
| 2024 Q1 | 1.41 Million CAD | -27.2% |
| 2023 Q3 | 858.42 Thousand CAD | -32.65% |
| 2023 Q2 | 1.27 Million CAD | 215.76% |
| 2023 Q1 | 403.64 Thousand CAD | -15.19% |
| 2023 FY | 1.94 Million CAD | 309.06% |
| 2023 Q4 | 1.94 Million CAD | 126.79% |
| 2022 Q2 | 432.43 Thousand CAD | -84.44% |
| 2022 Q1 | 2.77 Million CAD | 17.4% |
| 2022 FY | 475.91 Thousand CAD | -79.89% |
| 2022 Q4 | 475.91 Thousand CAD | -17.76% |
| 2022 Q3 | 578.66 Thousand CAD | 33.81% |
| 2021 Q4 | 2.36 Million CAD | 0.0% |
| 2021 FY | 2.36 Million CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 94.294% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 68.258% |
| SQZ Biotechnologies Company | 50.03 Million USD | 93.922% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 95.803% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 94.846% |
| Mesoblast Limited | 188.44 Million USD | 98.386% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 21.03% |
| Genus plc | 485 Million USD | 99.373% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 47.943% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -20.87% |
| Marizyme, Inc. | 26.67 Million USD | 88.598% |
| ContraFect Corporation | 32.53 Million USD | 90.651% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 19.961% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -53.509% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 20.539% |
| Intellipharmaceutics International Inc. | 12 Million USD | 74.673% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 74.177% |
| MultiCell Technologies, Inc. | 1617.67 USD | -187916.221% |
| Accustem Sciences Inc. | 1.07 Million USD | -181.817% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 96.071% |
| EV Biologics, Inc. | 2.11 Million USD | -43.801% |
| Q BioMed Inc. | 8.13 Million USD | 62.603% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 96.333% |
| Neon Bloom, Inc. | 1.22 Million USD | -148.039% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 40.897% |
| Biomind Labs Inc. | 1.49 Million USD | -102.953% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 98.754% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 83.473% |
| Skye Bioscience, Inc. | 14.07 Million USD | 78.387% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -51.308% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2040.457% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 67.869% |
| IMV Inc. | 37.93 Million USD | 91.982% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1412.302% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 47.066% |
| GB Sciences, Inc. | 5.41 Million USD | 43.859% |
| Alpha Cognition Inc. | 7.16 Million USD | 57.55% |
| HST Global, Inc. | 593.59 Thousand USD | -412.385% |
| CSL Limited | 18.62 Billion USD | 99.984% |
| Halberd Corporation | 728.71 Thousand USD | -317.374% |
| Enzolytics Inc. | 365.26 Million USD | 99.167% |
| Resverlogix Corp. | 67.39 Million USD | 95.487% |
| Affymax, Inc. | 8.87 Million USD | 65.714% |
| SYBLEU INC | 681.41 Thousand USD | -346.349% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -262.629% |
| argenx SE | 444.95 Million USD | 99.316% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 95.94% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -77.449% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 74.448% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 17.016% |
| AVAX Technologies, Inc. | 3.99 Million USD | 23.844% |
| Zenith Capital Corp. | 27.56 Thousand USD | -10932.254% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.771% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1174.432% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 18.553% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -346.729% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 97.438% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 66.363% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -4444.341% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -112.118% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 93.949% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -12.164% |
| BioStem Technologies, Inc. | 15.9 Million USD | 80.877% |
| ONE Bio Corp. | 27.49 Million USD | 88.938% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -554.506% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -10986.946% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -141.542% |
| Agentix Corp. | 2.51 Million USD | -21.148% |
| LadRx Corporation | 2.2 Million USD | -38.216% |
| Cell Source, Inc. | 15.8 Million USD | 80.758% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -6704.819% |
| Regen BioPharma, Inc. | 5.45 Million USD | 44.271% |
| Regen BioPharma, Inc. | 5.45 Million USD | 44.271% |
| NovAccess Global Inc. | 7.86 Million USD | 61.308% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 87.709% |
| Itoco Inc. | 1.65 Million USD | -83.981% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -48.252% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 49.719% |
| Kadimastem Ltd | 3.5 Million USD | 13.221% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -621.469% |
| CytoDyn Inc. | 127.89 Million USD | 97.622% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -7176.447% |
| Mobile Lads Corp. | 1.31 Million USD | -131.556% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -94.173% |
| Qrons Inc. | 1.48 Million USD | -104.303% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 72.464% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -276.052% |
| Rebus Holdings, Inc. | 5.24 Million USD | 41.979% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 50.155% |
| International Stem Cell Corporation | 5.27 Million USD | 42.363% |
| Bioxytran, Inc. | 3.24 Million USD | 6.402% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -386.008% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 34.126% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 92.581% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 86.34% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -50.168% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 44.478% |
| Neutra Corp. | 973.52 Thousand USD | -212.418% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 89.518% |
| PureTech Health plc | 125.58 Million USD | 97.578% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 19.048% |
| IXICO plc | 1.9 Million USD | -60.053% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 85.184% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 97.056% |
| CSL Limited | 18.62 Billion USD | 99.984% |
| Cellectis S.A. | 249.36 Million USD | 98.78% |